Navigation Links
ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Date:8/24/2007

LEUVEN, Belgium, August 24 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the seven month period ending 30 June 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

- Successful placing of a total of 5,166,517 shares, which increased the company's free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of EUR23.9m. These new funds have strengthened ThromboGenics financial position, and will allow it to continue to advance the development of its product portfolio and strengthen its operations. The company's cash position amounted to EUR49.3m as of 30 June 2007.

- Further progress with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of two Phase IIa clinical trials of microplasmin in Europe, for Vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively).

- Progressed TB-402 (anti-factor VIII) into man, in collaboration with BioInvent International. TB-402 is being developed as a potential anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation.

Financial summary

- For the December 2006 to June 2007 period, revenues amounted to EUR1.3m, mainly coming from out-licensing. Operating expenses were EUR10.5m, the majority of which were due to R&D expenses related to the microplasmin clinical development program. The net loss for the period was EUR8.6m.

- As of 30 June 2007, ThromboGenics had EUR49.3m in cash and cash equivalents. This compared to
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. While schools combat low tech enrollment, are businesses contributing to IT workforce woes?
2. CIOs focus on the business case while facing authority erosion
3. Surgical products company wins Governors Business Plan Contest
4. Business plan finalists capture technology
5. Speaker announces business members of IT Task Force
6. The business case for software applications
7. Turbo Tax Online can teach new Web concepts a business lesson
8. Former Fiserv exec to enter Business Hall of Fame
9. What does business want from the schools? Some answers may be surprising
10. Shades of gray: Business impacts of an aging workforce
11. Connectures Maynard finds IT business opportunity in adversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/21/2014)... have discovered how to produce ultra-thin "diamond nanothreads" that ... that of today,s strongest nanotubes and polymers. A paper ... John V. Badding, a professor of chemistry at Penn ... 2014 issue of the journal Nature Materials . ... is intriguing because the threads we formed have a ...
(Date:9/20/2014)... Austin, Texas (PRWEB) September 20, 2014 ... of integrated urological and interventional radiology products and ... Endocare, Inc. subsidiary with Clinicon Corporation ... addition expands HealthTronics’ portfolio of minimally invasive, mobile, ... their patients. , Under the agreement, HealthTronics will ...
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2
... 2011 Arecor, the leading company ... and vaccines, is pleased to announce the appointment ... Howell will be responsible for the operations of ... Arecor,s upward growth curve ensuring the company continues ...
... Nov. 10, 2011 Avaxia Biologics, Inc. , ... act locally within the gastrointestinal tract, announced today that ... of a Series A angel-led financing. Cherrystone Angels of ... Boston Harbor Angels and other undisclosed individuals. Mr. Robert ...
... Discovery Laboratories, Inc. (Nasdaq: DSCO ), ... respiratory critical care, today reports financial results for the third ... of the SURFAXIN® and AFECTAIR™ programs.  The Company will host ... call details are below. Selected third quarter highlights ...
Cached Biology Technology:Arecor Appoints Dr. Sarah Howell as Chief Operating Officer 2Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 3Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 4Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 5Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 6Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 7Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 8Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 9
(Date:9/22/2014)... in the country selected by the National Institutes ... Award a $2 million grant designed to ... sciences graduate trainees to career opportunities that go ... taken. , The award funds development of the ... program. It includes courses, seminars, shadowing, mentoring and ...
(Date:9/22/2014)... Evacuations of 2,819 people have occurred in the wake ... near the Eldorado National Forest. The King Fire ... of the American River Canyon, Silver Creek Canyon, and ... Pines. The fire has crossed into Placer County and ... Eldorado National Forest. The anticipated spread is expected to ...
(Date:9/21/2014)... General Assembly events focussed on ways to save and ... Challenges Canada, funded by the Government of Canada, today ... to address this challenge. , The novel approaches include: ... working in garment factories to express, pasteurize and store ... due to child illnesses, and lowering baby formula expense ...
Breaking Biology News(10 mins):Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 2Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 4Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 5Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 6Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 7Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 8Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 9Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 10Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 11Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 12Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 13Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 14Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 15
... 2010 Cellular imaging offers a wealth of data ... technique to study biological systems is a daunting challenge. ... Research ( www.genome.org ), researchers have developed a ... identify genetic interactions within biological networks, offering a glimpse ...
... in third-hand smoke, the residue from tobacco smoke that ... has been extinguished, reacts with the common indoor air ... potential health hazard was revealed in a multi-institutional study ... (Berkeley Lab). "The burning of tobacco releases nicotine ...
... Advanced maternal age is linked to a significantly elevated risk ... age, according to an exhaustive study of all births in ... Advanced paternal age is associated with elevated autism risk only ... 30, the study found. Published online today in the ...
Cached Biology News:Method of the future uses single-cell imaging to identify gene interactions 2Study reveals new details on the dangers of third-hand smoke 2Study reveals new details on the dangers of third-hand smoke 3Study reveals new details on the dangers of third-hand smoke 4UC Davis study confirms link between advanced maternal age and autism 2UC Davis study confirms link between advanced maternal age and autism 3UC Davis study confirms link between advanced maternal age and autism 4
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: